| Literature DB >> 8493036 |
K C Hayes1, A R Blight, P J Potter, R D Allatt, J T Hsieh, D L Wolfe, S Lam, J T Hamilton.
Abstract
4-Aminopyridine (4-AP) is a K+ channel blocking agent that enhances nerve conduction through areas of demyelination by prolonging the duration of the action potential and increasing the safety factor for conduction. We have investigated the effects of 4-AP (24 mg total dose-intravenous) in 6 patients with spinal cord injury (3 complete, 3 incomplete) with the intent of overcoming central conduction block, or slowing, due to demyelination. Vital signs remained stable and only mild side effects were noted. The 3 patients with incomplete injuries all demonstrated enhanced volitional EMG interference patterns and one patient exhibited restored toe movements. The changes were reversed on drug washout. There were no changes in segmental reflex activities. These results are consistent with those obtained from 4-AP trials with animal models of spinal cord injury, showing modest therapeutic benefit attributable to enhanced central conduction.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8493036 DOI： 10.1038/sc.1993.40
Source DB: PubMed Journal: Paraplegia ISSN： 0031-1758